QQQ4.80%

Trending

BTC3.57%

home Symbol DFTXnews

DFTXDefinium Therapeutics Inc.

$23.55

$1.04

(4.23%)

Today

Closed $23.55

$0.05

(0.21%)

After Hours

Updated: 07:31 PM EDT

Reported EarningsMay 7

Mkt Cap$2.68B

Vol4.18M

Fundamentals

Mkt Cap

$2.68B

Volume

52W High

$26.25

52W Low

$6.35

PE Ratio

-9.41

Avg. Volume

1.6M

EPS (Annual)

-$2.06

Rev/Employee

$0.00

Earnings

May 07

Info

News

all

press releases

Definium Therapeutics to Participate in the 2026 Jefferies Global Healthcare Conference

Definium Therapeutics, Inc. (NASDAQ: DFTX), a late-stage clinical biopharmaceutical company developing a new generation of therapeutics intended to address underlying causes of psychiatric and neurological disorders, today announced that members of the Companys management team will participate in a...

Business Wire

More News

Definium Therapeutics Announces First Patient Dosed in Ascend, the Second Phase 3 Pivotal Study of DT120 ODT in Major Depressive Disorder

Definium Therapeutics, Inc. (Nasdaq: DFTX) (Definium or the Company), a late-stage clinical biopharmaceutical company developing a new generation of therapeutics intended to address the underlying...

Business Wire

Definium Therapeutics Announces New Employee Inducement Grants

Definium Therapeutics, Inc. (Definium or the Company), a late-stage clinical biopharmaceutical company developing a new generation of therapeutics intended to address underlying causes of psychiatric...

Business Wire

Definium Therapeutics Reports First Quarter 2026 Financial Results and Recent Highlights

Definium Therapeutics, Inc. (Definium or the Company) (NASDAQ: DFTX), a late-stage clinical biopharmaceutical company developing a new generation of therapeutics intended to address underlying causes...

Business Wire

Definium Therapeutics to Report First Quarter 2026 Financial Results on May 7, 2026

Definium Therapeutics, Inc. (NASDAQ: DFTX), a late-stage clinical biopharmaceutical company developing a new generation of therapeutics intended to address underlying causes of psychiatric and neurological disorders, today announced that it will host a live webcast at 4:30 p.m. EDT on Thursday, May...

Business Wire

Definium Therapeutics, Inc. (NASDAQ:DFTX) Receives Consensus Recommendation of "Buy" from Analysts

Shares of Definium Therapeutics, Inc. (NASDAQ:DFTX - Get Free Report) have been given a consensus rating of "Buy" by the fifteen brokerages that are presently covering the firm, MarketBeat reports. One investment analyst has rated the stock with a sell recommendation, eleven have given a buy recom...

MarketBeat

Definium Therapeutics, Inc. (NASDAQ:DFTX) Short Interest Update

Definium Therapeutics, Inc. (NASDAQ:DFTX - Get Free Report) was the target of a large decline in short interest during the month of April. As of April 15th, there was short interest totaling 9,819,886 shares, a decline of 35.1% from the March 31st total of 15,129,638 shares. Currently, 10.1% of...

MarketBeat

Definium Therapeutics (NASDAQ:DFTX) Stock Price Down 6.7% - Here's What Happened

Definium Therapeutics (NASDAQ:DFTX) Shares Down 6.7% - Here's What Happened...

MarketBeat

Q1 Earnings Estimate for DFTX Issued By HC Wainwright

Definium Therapeutics, Inc. (NASDAQ:DFTX - Free Report) - Investment analysts at HC Wainwright issued their Q1 2027 earnings estimates for shares of Definium Therapeutics in a report issued on...

MarketBeat

Definium Therapeutics Investor Day: DT120 Phase III Readouts Set for Late Q2-Q3, PTSD Plan for 2027

Definium Therapeutics (NASDAQ:DFTX) used a company event to outline its late-stage development plans for DT120, an oral disintegrating tablet (ODT) formulation of LSD being studied for generalized anxiety disorder (GAD) and major depressive disorder (MDD), with an additional phase III study in post...

MarketBeat

...

Advertisement|Remove ads.